Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erbach

17 clinical trials in Erbach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erbach at a glance
17
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

17 trials in Erbach

Open in trial search

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Novartis Pharma AG

Psychotic disorder+1

Recruiting

Study of trospium chloride and xanomeline tartrate (KarXT) in patients with psychosis associated with Alzheimer's disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Effects of Vidofludimus Calcium (IMU-838) in Patients with Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Vidofludimus Calcium
  • Sponsor:Immunic AG

Psychotic disorder+1

Recruiting

Study on Long-Term Safety of KarXT (Trospium Chloride, Xanomeline Tartrate) for Patients with Alzheimer's-Related Psychosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Karuna Therapeutics Inc.

Oral Semaglutide in People With Mild Cognitive Impairment or Mild Dementia of the Alzheimer’s Type

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Parkinson's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Minzasolmin and Iodine Ioflupane (123I) in Patients with Parkinson's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ioflupane (123I)
  • Sponsor:UCB Biopharma

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:F. Hoffmann-La Roche AG

A Study to Test the Long-term Safety and Benefits of GSK4527226 in Patients with Early Alzheimer's Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK4527226
  • Sponsor:Glaxosmithkline Research & Development Limited

Migraine

Not recruiting

Study on Atogepant for Preventing Menstrual Migraine in Women

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Erbach

What the registry says about research in the country

01 Alzheimer's Disease Research

Groundbreaking clinical trials focusing on early Alzheimer's disease treatments and interventions for associated psychosis. Studies are evaluating novel compounds for managing cognitive decline and neuropsychiatric symptoms.

  • Early-stage disease intervention
  • Psychosis management
  • Cognitive function preservation

Multiple therapeutic approaches targeting both cognitive symptoms and behavioral manifestations of the disease.

02 Migraine Studies

Innovative research examining new treatments for menstrual migraine and chronic migraine conditions. Comparative studies evaluating the effectiveness of different preventive treatments.

  • Preventive treatment protocols
  • Medication comparison studies
  • Gender-specific approaches

Focus on developing targeted therapies for specific types of migraines and their prevention.

03 Multiple Sclerosis Initiatives

Comprehensive research programs investigating treatments for various forms of multiple sclerosis, including progressive and relapsing forms. Studies utilize advanced imaging techniques to track disease progression.

  • Progressive MS treatments
  • Brain atrophy assessment
  • Disability progression prevention

Advanced therapeutic approaches targeting different disease manifestations and progression patterns.

04 Parkinson's Disease Studies

Innovative research focusing on early-onset Parkinson's disease, examining long-term treatment efficacy and brain pathophysiology changes. Studies aim to understand disease progression and therapeutic interventions.

  • Early intervention strategies
  • Long-term treatment effects
  • Disease modification approaches

Emphasis on understanding disease mechanisms and developing targeted therapeutic solutions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.